Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2017

View Archived Issues

Preclinical characterization of a novel selective PI3Kalpha inhibitor, GDC-0077

LY-3214996 demonstrates potent antitumor activity in cancer models with MAPK pathway alterations

Discovery and preclinical characterization of novel JAK1 inhibitor AZD-4205

FDA approves Gilead Sciences' Harvoni and Sovaldi in pediatric patients

First data from first-in-human study of FGFR-4 inhibitor FGF-401 reported

Janssen identifies novel FGFR inhibitors

NSTDA patents dihydrofolate reductase inhibitors

Merck KGaA discloses new IRAK-1/4 inhibitors

IASOtoc now available in France, Austria and Germany

Phase II PREVACEbola vaccine study launched in West Africa to evaluate three vaccination strategies

Akorn and Fresenius Kabi in discussions regarding potential acquisition

PeptiDream and Janssen enter discovery and collaboration agreement

Kyowa Hakko Kirin announces positive results from the phase III MAVORIC clinical trial

Themis Bioscience initiates phase I dose-finding study of MV-ZIKA vaccine

Kura Oncology begins phase I study of KO-947 in nonhematological malignancies

Sunshine Lake Pharma, Calitor Sciences patent JAK, FLT-3 and Aurora kinase inhibitors

Medivir announces completion of phase II remetinostat study in CTCL

Assembly Biosciences, IURTC present HBV core protein modulators

Fred Hutch announces faculty and staff achievements

FDA issues complete response letter regarding Merck & Co.'s sitagliption sNDAs

Celgene describes in vivo antitumor activity of anti-CD47 monoclonal antibody CC-90002

Cipla and MEDRx enter into a collaboration for MRX-4TZT

Nanotherapeutics begins enrollment in phase I trial of NTM-1634

Indian FDA approves first autologous dendritic cell-based immuno-oncology product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...